Comparison · NCT01830621-sae
BBI608 vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. BBI608 vs Placebo: serious adverse events. Trial comparisons, record NCT01830621-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01830621-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.294 | 0.224 | 0.376 | wilson | |
| Risk in group 2 | 0.201 | 0.144 | 0.274 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0927 | -0.00837 | 0.192 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.46 | 0.963 | 2.22 | log | |
| Odds ratio, group 1 over group 2 | 1.65 | 0.954 | 2.86 | log | |
| Number needed to harm, for one more participant with a serious adverse event on BBI608 than on Placebo | 10.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | BBI608 | BBI608 480 mg two times daily (960 mg total daily dose)+ Best Supportive Care~BBI608~Best Supportive Care~At risk patients included only patients who received at least one dose of BBI608 | 40 | 136 | EG000 |
| Group 2 | Placebo | Placebo two times daily + Best Supportive Care~Placebo~Best Supportive Care~At risk patients included only patients who received at least one dose of placebo | 29 | 144 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 36 months
Source ClinicalTrials.gov
Trial
- Title
- BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma
- NCT number
- NCT01830621
- Phases
- PHASE3
- Conditions
- Colorectal Carcinoma
- Interventions
- BBI608, Placebo, Best Supportive Care
- Lead sponsor
- NCIC Clinical Trials Group
- Results first posted
- 2019-03-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01830621?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01830621-sae